AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04697043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic therapy followed by surgery if the disease is not progressive
Description: Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
Study NCT04304820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)
Study NCT04304820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response
Study NCT04304820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Horse-Anti-thymocyte-Globulin
Description: h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
Study NCT01109329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HMPV challenge virus
Description: Single dose of 10\^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
Study NCT00088907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV
Study NCT00088907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00088907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00088907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT04070755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-101
Study NCT02941887 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavior Analysis
Description: One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
Study NCT03930147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASV ventilation
Description: Ventilation on ASV mode
Study NCT01178320 — intervention group
Intervention type: DRUG
Intervention: Simvastatin, simvastatin plus extended-release niacin
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Study NCT05406388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
Study NCT05406388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
Study NCT04165590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium immunotherapy
Description: The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.
Study NCT02973425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase
Description: NRT sampling experience \& Suite of mHealth motivational tools and mini-games.
Study NCT02973425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NRT and mHealth assessment tool without feedback
Description: NRT and mHealth assessment tool without feedback
Study NCT04202952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 Tablet
Description: administered orally once daily
Study NCT04202952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir Tablet
Description: administered orally once daily
Study NCT03274609 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Augmented fluoroscopy
Description: Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
Study NCT01448213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
Study NCT01448213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorometholone
Description: Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
Study NCT02249754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
Study NCT02249754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine health education
Description: This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
Study NCT02249754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine health education
Description: This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
Study NCT03503513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
Study NCT03393715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Oral Tablet
Description: Perindopril oral tablet morning versus evening
Study NCT03393715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril Oral Tablet
Description: Perindopril oral tablet morning versus evening
Study NCT00929656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real rTMS
Description: rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
Study NCT00929656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
Study NCT00929656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unimanual paretic UE Training
Description: UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
Study NCT00929656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unimanual paretic UE Training
Description: UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
Study NCT00607880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vascular access device placement
Study NCT00607880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vascular access device placement
Study NCT04321980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: Subcutaneous injection of OP-101 in healthy volunteers
Study NCT01009892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Sulfate
Description: Tablet
Study NCT02405923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRF
Description: The subject will take the formula for a period of 12 months.
Study NCT02405923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: eHF
Description: The subject will take the formula for a period of 12 months.
Study NCT01123954 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal flu vaccine
Description: This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
Study NCT01096212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: original sevoflurane
Description: Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
Study NCT01096212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic sevoflurane
Description: Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
Study NCT00528164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team PLAY
Description: Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
Study NCT03138811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: inhaled once daily dose
Study NCT03138811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: inhaled once daily dose
Study NCT04121611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: 1. Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~2. Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)
Study NCT04121611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (ASA)
Description: 1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose
Study NCT00230438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Study NCT02488187 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ABUS
Description: Automated breast ultrasound
Study NCT03597971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL004-6599
Description: For each cohort, 6 subjects will receive HMPL004-6599
Study NCT03597971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each cohort, 2 subjects will receive placebo
Study NCT00659529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
Study NCT01681810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14Nitrogen Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
Study NCT06211192 — intervention group
Intervention type: OTHER
Intervention: retrospective data collection
Description: retrospective data collecting from medical records
Study NCT01288222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KIR genotype
Description: KIR genotype data from unrelated donor are collected
Study NCT02612051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008348 Nebuliser solution
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
Study NCT02612051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nebuliser solution
Description: 5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
Study NCT02612051 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Description: Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
Study NCT04155268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flotation-REST
Description: Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.
Study NCT04155268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dark Room
Description: Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
Study NCT02069925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Detection (ED)
Description: This intervention consists of educational campaigns directed at patients \& families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
Study NCT02069925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Detection
Description: This intervention will provide equivalent best practice care without the benefit of an early detection campaign
Study NCT02069925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Detection
Description: This intervention will provide equivalent best practice care without the benefit of an early detection campaign
Study NCT01768897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: Given IV
Study NCT01768897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01768897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT01768897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01768897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01726244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention
Description: Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
Study NCT04109365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrical Epidural Stimulation Test (EST)
Description: EST measures sensory/motor responses
Study NCT01386918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: The treatment involves the administration of a magnetic field applied to a specific area of the brain.
Study NCT01386918 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: The treatment involves the administration of a magnetic field applied to a specific area of the brain.
Study NCT04196803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks
Study NCT04196803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks
Study NCT01187069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training course for practice nurses in autonomy support
Description: An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
Study NCT03881228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing the completion of IPT
Description: Behavioral intervention with three components to increase the completion of IPT among children
Study NCT00618436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
Study NCT00618436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin
Description: The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
Study NCT04254588 — intervention group
Intervention type: OTHER
Intervention: Abdominal examination
Description: Examination by in-person physician vs. remote physician.
Study NCT01231256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive health consultation
Description: A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
Study NCT05370716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polmacoxib
Description: Polmacoxib
Study NCT05370716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polmacoxib
Description: Polmacoxib
Study NCT05370716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin
Study NCT05370716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin
Study NCT04465448 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
Study NCT03173066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
Study NCT03374995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT03374995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03374995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03374995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical Keratin
Description: Given topically
Study NCT00044551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane (Cytotoxic, BAY59-8862)
Description: Daily 1 h infusion every 3 weeks
Study NCT03517189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aorta no-touch
Description: Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
Study NCT02091154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USDA Regulations
Description: Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim